Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)
🇺🇸 After expanding to six countries this year, Vik Atopic Dermatitis completes the world tour with one more launch: the USA!
🌎 We’re proud of Vik AD‘s trajectory empowering thousands of people around the world with medically validated content, improving their quality of life, and providing support throughout their care journey.
Developed with the support of patients, associations, and healthcare professionals, our virtual companion:
☝️ Provides answers to all questions 24/7
🗣 Shares tips, daily inspiration, and patient testimonials
⏰ Helps patients monitor their illness (such as symptoms, treatment, appointment reminders, etc.).
We are thrilled to announce that Wefight has partnered with Kiplin! 🤝 Together, we are committed to facilitating lifestyle changes through physical activity for patients with chronic diseases!
[INNOVER CONTRE LE CANCER 5/5] Si certains acteurs se concentrent sur le diagnostic ou le traitement du cancer, d’autres développent des produits et services pour soulager le quotidien des patients. Maddyness a sélectionné une liste non exhaustive de solutions pour les accompagner dans la maladie.
We’re proud to announce a new partnership with Pierre Fabre Group!
Committed to acting alongside patients, Pierre Fabre takes another step towards giving them the possibility to play a more active role in caring for their health.
It’s launch day! 🚀 We’re proud to announce the launch of Vik Atopic Dermatitis in 3 new countries: Italy, Spain, and the United Kingdom!